- Tekmira Pharmaceuticals (TKMR -0.5%) enters into a Manufacturing and Clinical Trial Agreement with the University of Oxford to supply the TKM-Ebola-Guinea vaccine candidate for clinical studies in West Africa. 100 courses have been made and are now available to be used. The trials should begin in Q1.
- Separately, Health Canada clears the start of a Phase 1 trial assessing TKM-HBV in healthy volunteers. The trial should start in Q1. The study is expected to progress to chronically infected patients in H2 2015.